In vitro, NMN ameliorated agonist-induced cardiac hypertrophy in a Sirt7-dependent manner.
In plain wordsIn cells, NMN reduced agonist-induced cardiac hypertrophy through a process that depended on Sirt7.
- Outcome
- DecreaseAgonist-induced cardiac hypertrophy
- Study
n: not reported in source
cardiomyocytes- Outcome group
- Heart function · Cardiovascular
- Studied dose
- Dose not stated
Source sentences
Interestingly, we demonstrated that treatment with nicotinamide mononucleotide, a known key NAD+ intermediate, ameliorated agonist-induced cardiac hypertrophies in a Sirt7-dependent manner in vitro.